Alex A. Adjei
Cleveland Clinic · 781 works · 35,873 citations · h-index 94
Top works
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Blocking Oncogenic Ras Signaling for Cancer Therapy
- Targeting Apoptosis Pathways in Cancer Therapy
- Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
- Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
- A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
- Small Cell Lung Cancer
- Clinical Features of 5,628 Primary Lung Cancer Patients
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
- The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
- Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
- Metaplastic breast cancer: Prognosis and response to systemic therapy
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
- Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
- Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
- A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.